JPMorgan Chase & Co. Analysts Give MorphoSys (ETR:MOR) a €18.00 Price Target

MorphoSys (ETR:MORGet Rating) has been given a €18.00 ($18.56) price objective by stock analysts at JPMorgan Chase & Co. in a report issued on Monday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s target price indicates a potential upside of 16.17% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Berenberg Bank set a €65.00 ($67.01) price target on shares of MorphoSys in a research note on Thursday, August 4th. Deutsche Bank Aktiengesellschaft set a €18.00 ($18.56) target price on shares of MorphoSys in a research report on Monday, October 24th. Finally, The Goldman Sachs Group set a €24.00 ($24.74) price objective on shares of MorphoSys in a research note on Thursday, August 4th.

MorphoSys Stock Performance

ETR:MOR opened at €15.50 ($15.97) on Monday. The firm has a market cap of $529.21 million and a price-to-earnings ratio of -0.88. The company has a debt-to-equity ratio of 231.51, a current ratio of 2.98 and a quick ratio of 2.71. MorphoSys has a 1-year low of €16.08 ($16.57) and a 1-year high of €39.96 ($41.20). The firm’s fifty day moving average price is €19.71 and its 200 day moving average price is €19.90.

About MorphoSys

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Recommended Stories

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.